IceCure Medical (NASDAQ:ICCM) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Alliance Global Partners boosted their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a report on Wednesday, March 20th.

IceCure Medical Trading Down 3.7 %

NASDAQ:ICCM opened at $1.30 on Tuesday. The stock’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.66 and a quick ratio of 3.08. The stock has a market cap of $59.31 million, a PE ratio of -3.94 and a beta of 0.73. IceCure Medical has a fifty-two week low of $0.52 and a fifty-two week high of $1.57.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. IceCure Medical had a negative net margin of 453.76% and a negative return on equity of 86.96%. The business had revenue of $1.26 million for the quarter. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. As a group, equities research analysts forecast that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in shares of IceCure Medical in the second quarter valued at about $78,000. UBS Group AG grew its holdings in IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after buying an additional 26,919 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after buying an additional 20,000 shares during the last quarter. Finally, Bank of America Corp DE increased its position in IceCure Medical by 57.2% in the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after buying an additional 20,159 shares during the period. Institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.